Inhibition of interleukin-1β-induced matrix metalloproteinases 1 and 13 production in human osteoarthritic chondrocytes by prostaglandin D 2

Arthritis and Rheumatism

Volumn 58, Issue 11, 2008, Pages 3530-3540

  Zayed, Nadia ^a   Afif, Hassan ^a   Chabane, Nadir ^a   Mfuna Endam, Leandra ^a   Benderdour, Mohamed ^b   Martel Pelletier, Johanne ^a   Pelletier, Jean Pierre ^a   Motiani, Rajender K ^c   Trebak, Mohamed ^c   Duval, Nicolas ^d   Fahmi, Hassan ^a  

^a NOTRE DAME HOSPITAL   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^c ALBANY MEDICAL COLLEGE   (United States)

^d Centre de Convalescence   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

13,14 DIHYDRO 15 OXOPROSTAGLANDIN D2; 13,14 DIHYDRO 15 OXOPROSTAGLANDIN F2 ALPHA; 5 (6 CARBOXYHEXYL) 1 (3 CYCLOHEXYL 3 HYDROXYPROPYL)HYDANTOIN; 8 BROMO CYCLIC AMP; CELL PROTEIN; COLLAGENASE 3; CYCLIC AMP DEPENDENT PROTEIN KINASE; FORSKOLIN; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; KT 5720; MESSENGER RNA; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PROSTAGLANDIN D2; PROSTAGLANDIN D2 DERIVATIVE; PROTEIN CRTH2; PROTEIN DP1; UNCLASSIFIED DRUG; 13,14-DIHYDRO-15-KETOPROSTAGLANDIN D2; ANTIBODY; CARBAZOLE DERIVATIVE; CYCLIC AMP; DRUG DERIVATIVE; IMMUNOGLOBULIN RECEPTOR; ISOQUINOLINE DERIVATIVE; LEUKOTRIENE B4 RECEPTOR; LTB4R PROTEIN, HUMAN; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN RECEPTOR; PROSTANOID D RECEPTOR 1, HUMAN; PYRROLE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE CELL; CONTROLLED STUDY; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; OSTEOARTHRITIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TH2 CELL; BIOSYNTHESIS; CELL CULTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

8-BROMO CYCLIC ADENOSINE MONOPHOSPHATE; AGED; ANTIBODIES; CARBAZOLES; CELLS, CULTURED; CHONDROCYTES; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FORSKOLIN; HUMANS; INTERLEUKIN-1BETA; ISOQUINOLINES; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 13; OSTEOARTHRITIS; PROSTAGLANDIN D2; PYRROLES; RECEPTORS, IMMUNOLOGIC; RECEPTORS, LEUKOTRIENE B4; RECEPTORS, PROSTAGLANDIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SULFONAMIDES; TH2 CELLS;

EID: 55849114042     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.23958     Document Type: Article

References (42)

1. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci 2006;11:529-43.
2. Welgus HG, Jeffrey JJ, Eisen AZ. The collagen substrate specificity of human skin fibroblast collagenase. J Biol Chem 1981;256: 9511-5.
3. Knauper V, Lopez-Otin C, Smith B, Knight G, Murphy G. Biochemical characterization of human collagenase-3. J Biol Chem 1996;271:1544-50.
4. Reboul P, Pelletier JP, Tardif G, Cloutier JM, Martel-Pelletier J. The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes: a role in osteoarthritis. J Clin Invest 1996;97:2011-9.
5. Borden P, Solymar D, Sucharczuk A, Lindman B, Cannon P, Heller RA. Cytokine control of interstitial collagenase and collagenase-3 gene expression in human chondrocytes. J Biol Chem 1996;271:23577-81.
6. Brewster M, Lewis EJ, Wilson KL, Greenham AK, Bottomley KM. Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. Arthritis Rheum 1998;41:1639-44.
7. Sabatini M, Lesur C, Thomas M, Chomel A, Anract P, de Nanteuil G, et al. Effect of inhibition of matrix metalloproteinases on cartilage loss in vitro and in a guinea pig model of osteoarthritis. Arthritis Rheum 2005;52:171-80.
8. Ishikawa T, Nishigaki F, Miyata S, Hirayama Y, Minoura K, Imanishi J, et al. Prevention of progressive joint destruction in adjuvant induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR217840. Eur J Pharmacol 2005;508:239-47.
9. Ishikawa T, Nishigaki F, Miyata S, Hirayama Y, Minoura K, Imanishi J, et al. Prevention of progressive joint destruction in collagen-induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR255031. Br J Pharmacol 2005;144:133-43.
10. Hutchinson JW, Tierney GM, Parsons SL, Davis TR. Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. J Bone Joint Surg Br 1998;80:907-8.
11. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295: 2387-92.
12. Thabet MM, Huizinga TW. Drug evaluation: apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis. Curr Opin Investig Drugs 2006;7:1014-9.
13. Martel-Pelletier J, Pelletier JP, Fahmi H. Cyclooxygenase-2 and prostaglandins in articular tissues. Semin Arthritis Rheum 2003; 33:155-67.
14. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. Inducible cyclooxygenase may have antiinflammatory properties. Nat Med 1999;5:698-701.
15. Ianaro A, Ialenti A, Maffia P, Pisano B, Di Rosa M. Role of cyclopentenone prostaglandins in rat carrageenin pleurisy. FEBS Lett 2001;508:61-6.
16. Murakami Y, Akahoshi T, Hayashi I, Endo H, Hashimoto A, Kono S, et al. Inhibition of monosodium urate monohydrate crystal-induced acute inflammation by retrovirally transfected prostaglandin D synthase. Arthritis Rheum 2003;48:2931-41.
17. Kapoor M, Kojima F, Yang L, Crofford LJ. Sequential induction of pro- and anti-inflammatory prostaglandins and peroxisome proliferators-activated receptor-γ during normal wound healing: a time course study. Prostaglandins Leukot Essent Fatty Acids 2007;76:103-12.
18. Hirata M, Kakizuka A, Aizawa M, Ushikubi F, Narumiya S. Molecular characterization of a mouse prostaglandin D receptor and functional expression of the cloned gene. Proc Natl Acad Sci U S A 1994;91:11192-6.
19. Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001;193:255-61.
20. Crider JY, Griffin BW, Sharif NA. Prostaglandin DP receptors positively coupled to adenylyl cyclase in embryonic bovine tracheal (EBTr) cells: pharmacological characterization using agonists and antagonists. Br J Pharmacol 1999;127:204-10.
21. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49.
22. Fahmi H, Di Battista JA, Pelletier JP, Mineau F, Ranger P, Martel-Pelletier J. Peroxisome proliferator - activated receptor γ activators inhibit interleukin-1β-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. Arthritis Rheum 2001;44:595-607.
23. Trebak M, St J Bird G, McKay RR, Birnbaumer L, Putney JW Jr. Signaling mechanism for receptor-activated canonical transient receptor potential 3 (TRPC3) channels. J Biol Chem 2003;278: 16244-52.
24. Town MH, Casals-Stenzel J, Schillinger E. Pharmacological and cardiovascular properties of a hydantoin derivative, BW 245 C, with high affinity and selectivity for PGD2 receptors. Prostaglandins 1983;25:13-28.
25. Leff P, Giles H. Classification of platelet and vascular prostaglandin D2 (DP) receptors: estimation of affinities and relative efficacies for a series of novel bicyclic ligands. With an appendix on goodness-of-fit analyses. Br J Pharmacol 1992;106:996-1003.
26. Monneret G, Cossette C, Gravel S, Rokach J, Powell WS. 15R-methyl-prostaglandin D2 is a potent and selective CRTH2/DP2 receptor agonist in human eosinophils. J Pharmacol Exp Ther 2003;304:349-55.
27. 2 metabolite generated during inflammatory processes. J Biol Chem 2002; 277:10459-66.
28. Francois M, Richette P, Tsagris L, Raymondjean M, Fulchignoni-Lataud MC, Forest C, et al. Peroxisome proliferator-activated receptor-γ down-regulates chondrocyte matrix metalloproteinase-1 via a novel composite element. J Biol Chem 2004;279: 28411-8.
29. 2 in synovial fluid from patients with inflammatory joint disorders and osteoarthritis. Z Rheumatol 1984;43: 89-96.
30. 12,14-prostaglandin J2 for induction of human articular chondrocyte apoptosis in arthritis. J Biol Chem 2004;279:37939-50.
31. 2 by human osteoblasts and modulation of osteoprotegerin, RANKL, and cellular migration by DP and CRTH2 receptors. J Bone Miner Res 2005;20:672-81.
32. Pietila P, Moilanen E, Seppala E, Nissila M, Lepisto P, Laitinen O, et al. Differences in the production of arachidonic acid metabolites between healthy and rheumatic synovial fibroblasts in vitro: a preliminary study. Scand J Rheumatol 1984;13:243-6.
33. De Paulis A, Marino I, Ciccarelli A, de Crescenzo G, Concardi M, Verga L, et al. Human synovial mast cells. I. Ultrastructural in situ and in vitro immunologic characterization. Arthritis Rheum 1996; 39:1222-33.
34. 12,14-prostaglandin J2 inhibits Bay 11-7085-induced sustained extracellular signal-regulated kinase phosphorylation and apoptosis in human articular chondrocytes and synovial fibroblasts. J Biol Chem 2004;279:22399-403.
35. Jakob M, Demarteau O, Suetterlin R, Heberer M, Martin I. Chondrogenesis of expanded adult human articular chondrocytes is enhanced by specific prostaglandins. Rheumatology (Oxford) 2004;43:852-7.
36. Tasaki Y, Takamori R, Koshihara Y. Prostaglandin D2 metabolite stimulates collagen synthesis by human osteoblasts during calcification. Prostaglandins 1991;41:303-13.
37. Trivedi SG, Newson J, Rajakariar R, Jacques TS, Hannon R, Kanaoka Y, et al. Essential role for hematopoietic prostaglandin D2 synthase in the control of delayed type hypersensitivity. Proc Natl Acad Sci U S A 2006;103:5179-84.
38. Serni U, Mannoni A, Benucci M. Is there preliminary in-vivo evidence for an influence of nonsteroidal antiinflammatory drugs on progression in osteoarthritis? Part II. Evidence from animal models. Osteoarthritis Cartilage 1999;7:351-2.
39. Gencosmanoglu BE, Eryavuz M, Dervisoglu S. Effects of some nonsteroidal anti-inflammatory drugs on articular cartilage of rats in an experimental model of osteoarthritis. Res Exp Med (Berl) 2001;200:215-26.
40. Rashad S, Revell P, Hemingway A, Low F, Rainsford K, Walker F. Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet 1989;2:519-22.
41. Reijman M, Bierma-Zeinstra SM, Pols HA, Koes BW, Stricker BH, Hazes JM. Is there an association between the use of different types of nonsteroidal antiinflammatory drugs and radiologic progression of osteoarthritis? The Rotterdam Study. Arthritis Rheum 2005;52:3137-42.
42. Dingle JT. The effect of nonsteroidal antiinflammatory drugs on human articular cartilage glycosaminoglycan synthesis. Osteoarthritis Cartilage 1999;7:313-4.